🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Alan Tan

Rush University Medical Center

ORCID: 0000-0001-5925-8565

Also affiliated with Vanderbilt University, University of Chicago, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).”.

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4607
N/A
0.385DataRank · unranked
12 citations

Karla V. Ballman, Matt D. Galsky, Michael J. Morris, Ronald C. Chen, Timothy A. Chan +9 more

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps194
N/A
0DataRank · unranked
5 citations

Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D. Lewis, Alan Tan +10 more

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps5107
N/A
0DataRank · unranked
4 citations

Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D. Lewis, Alan Tan +10 more

Gut Microbes and the Liver Circadian Clock Partition Glucose and Lipid Metabolism

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.05.24.491361
N/A
0DataRank · unranked
2 citations

Sumeed Manzoor, Katherine Carroll, Orlando DeLeon, Sawako Miyoshi, Jun Miyoshi +8 more

Gut microbes and the liver circadian clock partition glucose and lipid metabolism

Journal of Clinical Investigation(2023)10.1172/jci162515
N/A
0DataRank · unranked
46 citations

Sumeed Manzoor, Katherine Carroll, Orlando DeLeon, Sawako Miyoshi, Jun Miyoshi +9 more

Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.tps589
N/A
0DataRank · unranked
1 citations

Karla V. Ballman, Scott T. Tagawa, Alan Tan, Bishoy M. Faltas, Arshin Sheybani +11 more

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4609
N/A
0DataRank · unranked
1 citations

Karla V. Ballman, Matt D. Galsky, Michael J. Morris, Srikala S. Sridhar, Ronald C. Chen +7 more

The Host-specific Microbiota is Required for Diet-Specific Metabolic Homeostasis

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.11.05.565654
N/A
0DataRank · unranked
1 citations

Bingqing Xie, Tyler J. Long, Marissa StGeorge, Alan Tan, Sumeed Manzoor +6 more

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps402
N/A
0DataRank · unranked
17 citations

Catherine M. Tangen, Abhishek Tripathi, Brian Shuch, Sumanta K. Pal, Pedro C. Barata +9 more

Microbiome mismatches from microbiota transplants lead to persistent off-target metabolic and immunomodulatory effects

Cell(2025)10.1016/j.cell.2025.05.014
N/A
0DataRank · unranked
48 citations

Mora Mocanu, Alan Tan, Ashley M. Sidebottom, Jason Koval, Hugo D Ceccato +18 more